Greater transparency for oncology clinical trials reporting

The CONSORT guidelines may not fully address the complexity of modern oncology studies and they lack requirements for details that would allow readers to make fully informed clinical decisions. As a result, The Lancet’s editorial teams plan to apply stricter scrutiny when evaluating oncology trials to ensure higher scientific rigor. This articles highlights which kind of contents abstract, methods and results section must contain. For example, an explicit definition of the primary endpoint  should be reported in the abstract, to ensure any early data presented via interim analyses, surrogate endpoints, or underpowered secondary endpoints are not interpretated as the definitive overall findings from the trial.

View the article

The Lancet Oncology, 27, 147-148

Recommended on behalf of EASE by Silvia Maina, Italy